MADINA DIXON: Open Payments
NPI 1912268350 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$744 in 22 payments from 10 companies in 2025. Trend: 2023 $605 · 2024 $208 · 2025 $744
Food & beverage: $744
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $263 |
| Sumitomo Pharma America, Inc. | 4 | $184 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $49 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Abbott Laboratories | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Novo Nordisk Inc | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
Products named: Veozah, GEMTESA, Auvelity, ONZETRA XSAIL, PROCLAIM, MOUNJARO, Saxenda, Phexxi.
Industry payments across MS — which companies pay providers there.
